Literature DB >> 32861704

Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients.

Cem Onal1, Gokhan Ozyigit2, Ozan Cem Guler3, Pervin Hurmuz2, Nese Torun4, Murat Tuncel5, Yemliha Dolek3, Yagiz Yedekci2, Ezgi Oymak6, Burak Tilki2, Fadil Akyol2.   

Abstract

PURPOSE: To evaluate the distribution of metastatic lymph nodes (LN) detected on 68Ga-PSMA-positron emission tomography/computed tomography (PET/CT) in treatment-naïve prostate cancer (PC) patients and to analyze the LN coverage rates of the pelvic fields defined in the GETUG trial and RTOG guidelines and a pelvic field extending superiorly from the L4/L5 interspace.
MATERIALS AND METHODS: 68Ga-PSMA-PET/CT images obtained at diagnosis of 138 PC patients were retrospectively analyzed. The number and locations of 68Ga-PSMA-positive LNs were co-registered with one single-planning CT. The numbers, locations, and sizes of LNs located outside the three pelvic volumes were investigated for the entire cohort and for patients with LN metastasis in the pelvic area only.
RESULTS: A total of 441 PSMA-PET-positive LN metastases were identified. The most frequent metastatic LNs were internal iliac LNs (25.2%). Para-aortic and presacral LNs outside the three pelvic fields were present in 20 (14.5%) and 22 patients (15.9%), respectively. The LN coverage rates according to the GETUG trial, the RTOG guidelines, and the pelvic field extending superiorly from L4/L5 were 44.2%, 52.2%, and 71, respectively, in the entire cohort and 51.7%, 61 and 83.1%, respectively, in patients with only pelvic LN metastasis. The number of metastatic LNs was a predictive factor for LNs located outside the three pelvic fields.
CONCLUSIONS: Extending the cranial margin of the pelvic field from L5/S1 to L4/L5 increases the accuracy of pelvic field irradiation in approximately 20% of patients, highlighting the importance of proximal common iliac irradiation, particularly in patients with multiple LN metastasis.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen; Radiotherapy; Treatment volume

Mesh:

Substances:

Year:  2020        PMID: 32861704     DOI: 10.1016/j.radonc.2020.08.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

Review 1.  Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.

Authors:  Thomas S C Ng; Xin Gao; Keyan Salari; Dimitar V Zlatev; Pedram Heidari; Sophia C Kamran
Journal:  Front Oncol       Date:  2021-07-28       Impact factor: 6.244

2.  Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients.

Authors:  Cem Onal; Gokhan Ozyigit; Ezgi Oymak; Ozan Cem Guler; Burak Tilki; Pervin Hurmuz; Fadil Akyol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-10       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.